This function of AP‐2 is independent of its role in BACE1 endocytosis and requires its association with LC3‐containing autophagosomes, suggesting a combined pharmacological targeting of endocytic adaptors and autophagy as a new therapy for reducing the levels of Aβ in the AD brain. This evidence concerns the gene BACE1 and Alzheimer disease.